Drug
Halobetasol Propionate
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Psoriasis | 183 | 22.0 | 25.3 | signal |
| 2 | Dermatitis Atopic | 63 | 19.8 | 20.7 | signal |
| 3 | Skin Haemorrhage | 17 | 18.5 | 18.7 | signal |
| 4 | Skin Fissures | 22 | 18.3 | 18.6 | signal |
| 5 | Skin Lesion | 26 | 15.0 | 15.3 | signal |
| 6 | Psoriatic Arthropathy | 38 | 14.8 | 15.2 | signal |
| 7 | Drug Eruption | 14 | 12.5 | 12.6 | signal |
| 8 | Dermatitis Contact | 9 | 12.4 | 12.5 | signal |
| 9 | Seasonal Allergy | 11 | 12.2 | 12.3 | signal |
| 10 | Tenderness | 8 | 12.0 | 12.1 | signal |
| 11 | Eczema | 37 | 11.6 | 11.9 | signal |
| 12 | Scratch | 7 | 10.6 | 10.7 | signal |
| 13 | Sciatica | 10 | 9.9 | 10.0 | signal |
| 14 | Scab | 7 | 9.7 | 9.7 | signal |
| 15 | Skin Exfoliation | 51 | 9.6 | 10.0 | signal |
| 16 | Therapeutic Product Effect Incomplete | 39 | 8.7 | 8.9 | signal |
| 17 | Conjunctivitis | 9 | 7.7 | 7.7 | signal |
| 18 | Injection Site Discomfort | 5 | 7.6 | 7.6 | signal |
| 19 | Laryngitis | 5 | 7.2 | 7.3 | signal |
| 20 | Eye Pruritus | 15 | 7.1 | 7.2 | signal |
| 21 | Dermatitis | 9 | 6.8 | 6.9 | signal |
| 22 | Sleep Disorder Due To A General Medical Condition | 7 | 6.8 | 6.8 | signal |
| 23 | Impaired Quality Of Life | 6 | 6.5 | 6.6 | signal |
| 24 | Dry Skin | 53 | 6.3 | 6.5 | signal |
| 25 | Multiple Sclerosis | 19 | 6.2 | 6.3 | signal |
| 26 | Full Blood Count Abnormal | 4 | 6.0 | 6.0 | signal |
| 27 | Treatment Failure | 31 | 5.9 | 6.0 | signal |
| 28 | Rebound Effect | 4 | 5.5 | 5.6 | signal |
| 29 | Anhedonia | 9 | 5.3 | 5.4 | signal |
| 30 | Pain Of Skin | 9 | 5.2 | 5.3 | signal |
| 31 | Therapeutic Response Shortened | 10 | 4.9 | 5.0 | signal |
| 32 | Application Site Pain | 6 | 4.3 | 4.3 | signal |
| 33 | Skin Irritation | 12 | 4.1 | 4.1 | signal |
| 34 | Drug Toxicity | 3 | 3.4 | 3.4 | no signal |
| 35 | Injection Site Urticaria | 5 | 3.2 | 3.2 | signal |
| 36 | Device Failure | 3 | 3.1 | 3.1 | no signal |
| 37 | Needle Issue | 5 | 2.7 | 2.8 | no signal |
| 38 | Multiple Sclerosis Relapse | 11 | 2.5 | 2.5 | signal |
| 39 | Injection Site Swelling | 12 | 2.5 | 2.5 | signal |
| 40 | Injection Site Pain | 47 | 2.4 | 2.5 | signal |
| 41 | Injection Site Pruritus | 9 | 2.1 | 2.1 | signal |
| 42 | Exposure Via Skin Contact | 3 | 2.1 | 2.1 | no signal |
| 43 | Injection Site Bruising | 10 | 2.0 | 2.0 | no signal |
| 44 | Injection Site Erythema | 15 | 1.9 | 1.9 | no signal |
| 45 | Injection Site Haemorrhage | 8 | 1.6 | 1.6 | no signal |
| 46 | Drug Abuse | 7 | 1.3 | 1.3 | no signal |
| 47 | Device Breakage | 3 | 1.2 | 1.2 | no signal |
| 48 | Wrong Technique In Device Usage Process | 3 | 1.0 | 1.0 | no signal |